Alaunos Therapeutics, Inc.
TCRT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.28
KIRA · Stoqly’s AI analyst, in plain words
- Alaunos Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 50.0% on the year before.
- Its operating margin was −84,500.0%, down 36,380.0 pts: of every 100 in sales, about −84,500 is left after running the business.
- Alaunos Therapeutics, Inc. lost $4.2M in fiscal 2025.
- Free cash flow was −$3.0M in fiscal 2025, −59,340.0% of revenue.
Market cap
$5.5M
P/E
—
Revenue
$0.0M
Net income
−$4.2M
Free cash flow
−$3.0M
Operating margin
−84,500.0%
Alaunos Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−50.0%
No. Sales fell 50.0% last year.
Does it make a profit?
−83,520.0%
No. It lost money last year.
Does profit turn into cash?
−59,340.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alaunos Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Alaunos Therapeutics, Inc.
- CIK
- 0001107421
Alaunos Therapeutics, Inc. · TCRT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $2.9M | $0.0M | $0.0M | $0.0M |
| Revenue growth | — | 634.2% | −99.8% | 100.0% | −50.0% |
| Operating margin | −19,484.7% | −1,201.4% | −685,340.0% | −48,120.0% | −84,500.0% |
| Net income | −$78.8M | −$37.7M | −$4.7M | −$4.7M | −$4.2M |
| Net margin | −19,786.7% | −1,291.2% | −93,580.0% | −46,790.0% | −83,520.0% |
| Diluted EPS | −$0.37 | −$2.61 | −$21.97 | −$2.92 | −$2.20 |
| Cash | |||||
| Cash from operations | −$61.5M | −$29.2M | −$30.1M | −$5.0M | −$2.9M |
| Capital expenditure | $3.3M | $0.2M | $0.2M | $0.0M | $0.1M |
| Free cash flow | −$64.8M | −$29.4M | −$30.3M | −$5.0M | −$3.0M |
| FCF margin | −16,279.1% | −1,007.8% | −606,780.0% | −49,710.0% | −59,340.0% |
| Share buybacks | $0.0M | $0.0M | $0.0M | — | — |
| Share count change | 2.3% | −93.2% | −89.0% | 0.1% | 21.7% |
| Debt and strength | |||||
| Cash and short-term investments | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Debt incl. finance leases | $24.1M | $16.8M | $0.0M | $0.0M | — |
| Shareholders' equity | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
| Current ratio | 4.9x | 2.2x | 4.2x | 4.0x | 2.4x |
| Interest coverage | −65.2x | −11.1x | −17.8x | — | — |
| Returns and quality | |||||
| Return on capital | −1,000.9% | −170.5% | −11,049.4% | −391.1% | — |
| Return on equity | −86.5% | −78.1% | −20.9% | −111.8% | −198.1% |
| Return on tangible equity | −135.6% | −97.9% | −74.2% | −226.8% | −198.9% |
| Piotroski F-score | 2 | 4 | 4 | 1 | 2 |
| Altman Z'' | −28.5 | −43.3 | −380.8 | −1,092.9 | −1,020.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alaunos Therapeutics, Inc. · TCRT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.28 a share, the company is worth $5.5M.
Source: SEC EDGAR XBRL filings (CIK 0001107421). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.